Acadia Pharmaceuticals | ACAD - Cash And Equivalent


Acadia Pharmaceuticals reported $976.45M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
ALKERMES USD 631.31M 119.78M Sep/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
Biogen USD 1.3B 18.9M Sep/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Bristol-Myers Squibb USD 9.57B 852M Sep/2026
Cara Therapeutics USD 22.28M 2.42M Sep/2026
Corcept Therapeutics USD 98.72M 12.32M Sep/2026
Cytokinetics USD 203.43M 51.84M Sep/2026
Eisai JPY 245.42B 56.22B Mar/2026
Eli Lilly USD 4.89B 4.07B Sep/2026
Incyte USD 3.85B 127.8M Sep/2026
J&J USD 16.91B 3.51B Sep/2026
Moderna USD 1.2B 528M Sep/2026
Neurocrine Biosciences USD 641.5M 309.1M Sep/2026
Pfizer USD 1.82B 848M Sep/2026
Prothena USD 271.37M 16.82M Sep/2026
PTC Therapeutics USD 508.89M 540.99M Sep/2026
Sarepta Therapeutics USD 472.76M 98.39M Sep/2026
Ultragenyx Pharmaceutical USD 150M 25M Sep/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Vertex Pharmaceuticals USD 6.3B 1.55B Sep/2026